News | May 03, 2025
Zydus Lifesciences completes 25 years of listing on NSE
Over the last 24 years, the company's sales has grown from Rs. 478 crores to Rs. 19,022 crores
Over the last 24 years, the company's sales has grown from Rs. 478 crores to Rs. 19,022 crores
30th Lab in Thyrocare’s expanding network to bring advanced, affordable diagnostics in Bihar and beyond
Breztri is an inhaled triple-combination therapy approved for the treatment of chronic obstructive pulmonary disease
This significant milestone enhances our global regulatory standing
The Q1 2025 also witnessed a successful launch of Allegra D
Niacin is indicated to reduce elevated total cholesterol, LDL cholesterol, apolipoprotein B and triglycerides (TG)
Phesgo label expansion delivers on patients’ preference for at-home administration and is an important step in freeing up cancer care capacity in clinical settings
Priced at just Rs. 499 for 1-year supply, this initiative is aligned with the vision of Health for All
The transaction structured as share swap, is valued at ~Rs. 849 crore, with no cash outflow
The Board has also approved plans to invest approximately Rs. 500 crores including cost of land in developing a state-of-the-art, 400-bed super specialty hospital
Subscribe To Our Newsletter & Stay Updated
